

## METHOD DEVELOPMENT AND VALIDATION OF SORAFENIB IN MARKET FORMULATION

Alufa Tahreem\*<sup>1</sup>, Dr. Osman Ahmed<sup>1</sup> and Dr. Anas Rasheed<sup>2</sup>

<sup>1</sup>Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

<sup>2</sup>CSO, Gaelib Medications Private Limited, Hyderabad.



\*Corresponding Author: Alufa Tahreem

Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

Article Received on 06/11/2024

Article Revised on 26/11/2024

Article Accepted on 16/12/2024

### ABSTRACT

**Background:** Sorafenib is a multi-kinase inhibitor widely used in oncology. Developing robust analytical methods for its quantification ensures quality and efficacy in pharmaceutical formulations. Ultra-performance liquid chromatography (UPLC) is an advanced technique offering high precision and sensitivity for such analyses. **Aim:** This study aims to develop and validate a UPLC-based method for Sorafenib quantification, evaluating its precision, accuracy, linearity, robustness, and ruggedness. **Research Methodology:** A UPLC system with a C18 stationary phase was utilized. Methanol and acetonitrile (55:45, %v/v) served as the mobile phase. UV detection was performed at 240 nm with prednisolone as the internal standard. Retention times for Sorafenib and prednisolone were 7.292 and 2.645 minutes, respectively. Validation studies adhered to ICH guidelines, demonstrating recovery rates of 99.62–99.87%, a linearity coefficient of 0.9992, and a %RSD of 0.23% for ruggedness. **Conclusion:** The developed UPLC method is accurate, precise, and reproducible, proving its utility for routine quality control of Sorafenib in pharmaceutical formulations.

**KEYWORDS:** Sorafenib, UPLC, Validation.

### INTRODUCTION

Sorafenib is an oral multi-kinase inhibitor that targets pathways critical for tumor cell proliferation and angiogenesis. It is approved for treating advanced hepatocellular carcinoma, renal cell carcinoma, and thyroid carcinoma. The drug's therapeutic efficacy is dependent on accurate dosing and quality control, making robust analytical methods indispensable in pharmaceutical industries.

Ultra-performance liquid chromatography (UPLC) is a sophisticated analytical technique that has revolutionized chromatographic analysis. Compared to high-performance liquid chromatography (HPLC), UPLC employs smaller particle sizes, enhancing efficiency, sensitivity, and resolution while reducing analysis time. This advantage makes UPLC an excellent choice for pharmaceutical quality control, particularly for critical drugs like Sorafenib.

A reliable UPLC method requires comprehensive development and validation, ensuring reproducibility and accuracy across diverse conditions. Parameters such as linearity, precision, robustness, and detection limits are evaluated to confirm the method's applicability for

routine analysis. By aligning with regulatory guidelines, such as those of the International Council for Harmonisation (ICH), the validated method can ensure compliance and reliability in pharmaceutical quality assurance.

This study focuses on developing and validating a UPLC method for Sorafenib quantification in pharmaceutical formulations, emphasizing its precision, accuracy, and robustness.

### METHODOLOGY

**MATERIALS AND REAGENTS:** Analytical-grade methanol, acetonitrile, and prednisolone (internal standard) were procured. Standard Sorafenib samples were obtained from a certified supplier. Mobile phases were prepared by mixing methanol and acetonitrile in a 55:45 (%v/v) ratio.

**Instrumentation:** The chromatographic analysis was performed on a UPLC system equipped with a C18 column (stationary phase) and a UV detector set at 240 nm. The system's flow rate was maintained at 1.2 mL/min at ambient temperature.

**Method Development:** The mobile phase composition of methanol and acetonitrile in a 55:45 (%v/v) ratio provided optimal peak resolution and baseline separation. Sorafenib and the internal standard (prednisolone) showed retention times of 7.292 minutes and 2.645 minutes, respectively.

#### Validation Studies

**1. Accuracy:** Recovery studies at three levels (50%, 100%, and 150%) showed mean recovery rates of 99.74%, confirming the method's reliability.

**2. Precision:** System precision exhibited a %RSD of 0.33%, while method precision demonstrated a %RSD of 0.48%, validating consistency.

**3. Linearity:** Sorafenib displayed excellent linearity over the concentration range of 8–40 µg/mL with a correlation coefficient of 0.9992.

**4. Robustness:** Variations in flow rate, temperature, and wavelength caused minimal deviations, confirming robustness.

**5. Ruggedness:** Inter- and intraday precision analyses yielded %RSD values of 0.28–0.33%, demonstrating method ruggedness.

**6. Detection Limits:** The LOD and LOQ were determined as 0.838µg/mL and 2.540µg/mL, respectively.

## RESULTS

| SORAFENIB                         |   |
|-----------------------------------|---|
| <i>Method development by UPLC</i> |   |
| <b>System</b>                     | UPLC  |
| <b>Stationary Phase</b>           | C18   |
| <b>“Mobile Phase”</b>             | “Methanol and Acetonitrile in the ratio of 55:45 %v/v”                      |
| <b>Internal Standard</b>          | Prednisolone  |
| <b>Injection volume</b>           | 20µl  |
| <b>Temperature</b>                | Ambient   |
| <b>Flow rate</b>                  | 1.2 mL/min  |
| <b>UV detection</b>               | 240 nm  |
| <b>Retention Time</b>             | SORAFENIB– 7.292mins; Prednisolone – 2.645 mins                             |
| <b>Inference</b>                  | “Better resolution of the peaks with clear base line separation was found.” |

### > Validation Studies for SORAFENIB

#### Accuracy Procedure

| Recovery level | Set No. | SORAFENIB         |                      |
|----------------|---------|-------------------|----------------------|
|                |         | Wt. Taken (µg/ml) | Amount found (µg/ml) |
| 50%            | Set 1   | 08.09             | 08.06                |
|                | Set 2   | 08.07             | 08.05                |
|                | Set 3   | 08.08             | 08.04                |
| 100%           | Set 1   | 16.12             | 16.10                |
|                | Set 2   | 16.14             | 16.12                |
|                | Set 3   | 16.16             | 16.15                |
| 150%           | Set 1   | 24.25             | 24.22                |
|                | Set 2   | 24.27             | 24.25                |
|                | Set 3   | 24.29             | 24.27                |

#### System Precision

##### Procedure

| Parameters                 | SORAFENIB      |
|----------------------------|----------------|
| Theoretical plates ± % RSD | 2312.82 ± 0.50 |
| Asymmetry ± % RSD          | 1.07 ± 0.02    |
| Repeatability (% RSD)      | 0.33           |

#### Linearity

| SORAFENIB       |                        |       |
|-----------------|------------------------|-------|
| Linearity level | Concentration in µg/mL | Area  |
| 1               | 8 µg/mL                | 23266 |
| 2               | 16 µg/mL               | 29237 |
| 3               | 24 µg/mL               | 35123 |
| 4               | 32 µg/mL               | 42445 |
| 5               | 40 µg/mL               | 47168 |

|                          |         |
|--------------------------|---------|
| Correlation co-efficient | 0.9992  |
| Slope                    | 7626.93 |
| Intercept                | 17186.5 |

**Robustness**


| Robustness Studies |        |           |       |
|--------------------|--------|-----------|-------|
| Parameter          | Value  | Peak Area | % RSD |
| Flow Rate          | Low    | 29541     | 0.02% |
|                    | Actual | 29546     |       |
|                    | Plus   | 29551     |       |
| Temperature        | Low    | 29392     | 0.05% |
|                    | Actual | 29406     |       |
|                    | Plus   | 28420     |       |
| Wavelength         | Low    | 29604     | 0.01% |
|                    | Actual | 29609     |       |
|                    | Plus   | 29612     |       |

**Ruggedness**

| SORAFENIB                                 |           |       |              |
|---|-----------|-------|--------------|
| Ruggedness                                |           |       |              |
| Parameter                                 | Peak Area | % RSD | %LC          |
| Intraday precision                        | 29326     | 0.33% | 98.97%       |
|   | 29453     |       | 99.54%       |
|   | 29519     |       | 99.31%       |
| Inter day precision                       | 29371     | 0.28% | 99.81%       |
|   | 29434     |       | 99.60%       |
|   | 29532     |       | 99.27%       |
| Instrument:1<br>Acquity UPLC Waters,2695H | 29548     | 0.02% | 99.22%       |
|   | 29554     |       | 99.20%       |
|   | 29541     |       | 99.24%       |
| Instrument:2<br>Agilent Technologies,1290 | 29546     | 0.01% | 99.22%       |
|   | 29552     |       | 99.20%       |
|   | 29547     |       | 99.22%       |
| <b>Average</b>                            |           |       | <b>99.31</b> |
| <b>Std. Dev</b>                           |           |       | <b>0.225</b> |
| <b>%RSD</b>                               |           |       | <b>0.23%</b> |

**LOD and LOQ: LOD:**  $LOD = 3.3 * (1936.58 / 7622.875)$ ,  
 $LOD = 3.3 * (0.2540485)$ ,  $LOD = 0.83836 (\mu\text{g/ml})$

**LOQ:**  $LOQ = 10 * (SD/S)$ ,  $LOQ = 10 * (1936.58 / 7622.875)$ ,  
 $LOQ = 2.54048 (\mu\text{g/ml})$

**Assay Studies: Market**

## EVALUATION OF METHODS

## Assay Studies

## &gt; Analysis of SORAFENIB

| Conditions | Sample Amount (µg/ml) | Peak Area | % claim | % Degradation |
|------------|-----------------------|-----------|---------|---------------|
| Market     | 15.89                 | 26874     | 90.42%  | 8.91%         |

$$\% \text{ Assay} = \frac{AT}{AS} \times \frac{W1}{100} \times \frac{1}{25} \times \frac{100}{W2} \times \frac{25}{1} \times \frac{AW}{LC} \times P$$

Market (SORAFENIB): % Assay = 90.42%

## CONCLUSION

The developed UPLC method for Sorafenib quantification demonstrates excellent precision, accuracy, and robustness. Validation studies confirmed compliance with ICH guidelines, proving the method's reliability for routine quality control in pharmaceutical formulations. This method offers a robust analytical tool to ensure the quality and efficacy of Sorafenib in therapeutic applications.

## REFERENCES

1. Y. C. Mayur\*, Osman Ahmad, V. V.S. Rajendra Prasad, M. N. Purohit, N. Srinivasulu, S. M. Shanta Kumar, "Synthesis of 2-Methyl N10 -Substituted Acridones as Selective Inhibitors of Multidrug Resistance (MDR) Associated Protein in Cancer Cells". Medicinal Chemistry, Bentham Science Publishers, 2008; 4(5): 457-465(9).
2. Osman Ahmed\*, Pankaj Sharma, Jaya Sharma, "Synthesis and Pharmacological Study of Azetidinone Derivatives" International Journal of Pharmaceutical Science & Education, 2013; 11-18.
3. Osman Ahmed\*, Pankaj Sharma, Jaya Sharma, Dr. Indrajeet Singhvi, "Synthesis and Anticonvulsant Activity of Some Substituted Azetidinone Derivatives" Asian Journal of Pharmaceutical Research and Development, 2013; 5.
4. Osman Ahmed\*, Dr. Md Salahuddin, Vinutha. K, Pankaj Sharma. "Design, Synthesis and Biological Evaluation of Some Novel Substituted Thiazolidinone Derivatives as Potent Antihyperglycemic Agents". International Journal of Pharmaceutical Research Scholars, 2013; 2(3).
5. Osman Ahmed\*, Md Salahuddin, Pankaj Sharma, Indrajeet Singhvi "Synthesis and biological investigations of some new thiazolidinone derivatives as anti-tubercular agents", American Journal of Pharmtech Research, 2013; 3: 193-201.
6. Osman Ahmed\*, Md. Salahuddin, Iffath Rizwana, M.A. Aleem, Pankaj Sharma, "Synthesis, Characterization and Biological Evaluation of Novel thiazolidinone derivatives as Anti-inflammatory Agents", Indo American Journal of Pharmaceutical Research, 2013; 3(10): 8121-8126.
7. Osman Ahmed\*, Pankaj Sharma, Indrajeet Singhvi. "Synthesis and Anti-Hyperglycemic activity of Some Novel Thiazolidinone Derivatives". Indo American Journal of Pharmaceutical Research, 2014; 4(02): 1008-1014.
8. Osman Ahmed\*, Pankaj Sharma, Indrajeet Singhvi. "Anticonvulsant Activity of Some Novel Substituted Thiazolidinone Derivatives against Maximal Electro Shock Induced Seizure". International Journal of Pharmaceutical Research Scholars, 2014; 3(1): 289-294.
9. Osman Ahmed\*, Mohd Haseeb Ur Rahman, Abdul Najeeb, Sk. Md. Noorullah, S.A.Azeez Basha, Design, "Synthesis and Anti- inflammatory activity of certain fused Novel Thienopyrimidines Derivatives", International Journal of Pharmaceutical Research Scholars, 2013; 2(4): 82-87.
10. Syed Aamer Ali, SK Danda, Syed Abdul Azeez Basha, Rasheed Ahmed, Osman Ahmed, Mohd Muqtader Ahmed. "Comparision of uroprotective activity of reduced glutathione with Mesna in Ifosfamide induced hemorrhagic cystitis in rats". Indian Journal of Pharmacology, 2014; 46: 105-108.
11. Osman Ahmed\*, Syed Azeemuddin Razvi, T K Md Rayees, M A Nafay Shoeb, Md Salahuddin. "Synthesis Characterization and Anti-inflammatory activity of some substituted pyrimidine derivatives". Indo American Journal of Pharmaceutical Research, 2014; 4(05): 2301-2306. DOI: 10.1044/1980-iajpr.14369.
12. Osman Ahmed\*, Farhana Begum, Nishat Fatima, Md. Salahuddin. "Synthesis and Biological Activity of Some Novel Pyrimidine Derivatives". International Journal of Pharmaceutical Research Scholars, 2014; 3(4): 103-108.
13. Ms. Farhana Begum, Osman Ahmed, Md. Salahuddin, Nishat Fatima. "Synthesis, Characterization and Anti-Hyperglycemic Activity of Novel Pyrimidine Derivatives". Indo American Journal of Pharm Research, 2014; 4(11): 5501-5506. DOI: 10.1044/19 80-iajpr.141042
14. Osman Ahmed\*, Mehruq Fatima, Juveriya Parveen, Asma Farheen, Ayesha Binth Saleh, Dr. Syed Mahmood Ahmed. Changes in Pulmonary Function Test (PFT) Before and After Adding Tiotropium Bromide to the Ongoing Therapy of Severe Persistant Asthamatics. Indo American Journal of Pharm Research, 2015; 5(01). DOI: 10.1044/1980-iajpr.141266.
15. Mohd Khader, Mohd Mahboob Shareef, Syeda Huda Noorain, Osman Ahmed. Synthesis, Characterization and Biological Activity of Some Novel Pyrimidine

- Derivatives. *Indo American Journal of Pharm Research*, 2015; 5(03).
16. Fayeza Batool, Osman Ahmed, Anas Rasheed. An Assay Method for the Simultaneous Estimation of Acetaminophen and Tramadol using RP-HPLC Technology. *Indo American Journal of Pharmaceutical Research*, 5(7): 2605-2610.
  17. Fayeza Batool, Osman Ahmed, Anas Rasheed. A Stability Indicating Method for the Simultaneous Estimation of Acetaminophen and Tramadol in Pharmaceutical Dosage Form. *American Journal of PharmTech Research*, 2015; 5(04): 674-683.
  18. Humeera Rafeeq, Talath Fatima, Afiya Ansari, Osman Ahmed. Personalized Medicine - A Boon For Treating Rheumatoid Arthritis. *Indo American Journal of Pharmaceutical Research*, 5(8).
  19. Humeera Rafeeq, Osman Ahmed, M.A Khaleq, Samee A, Amer M. Progress In The Treatment of Neuroblastoma. *Indo American Journal of Pharmaceutical Research*, 5(8).
  20. Talath Fatima, Osman Ahmed, Amer Mahboob, Afiya Ansari, Amatullah Fathimah. Personalized Medicine - A Review – Progress In The Treatment of Non-Small Cell Lung Cancer (NSCLC) In A New Era of Personalised Medicine. *Indo American Journal of Pharmaceutical Research*, 5(8).
  21. Talath Fatima\*, Osman Ahmed, Afiya Ansari, Amatullah Fathimah, Amer Mahboob. Novel Therapeutic Approaches to a Chronic Inflammatory Disorder – Asthma. *International Journal of Pharmaceutical Research Scholars*, 2015; 4(3): 112-117.
  22. Humeera Rafeeq\*, Osman Ahmed, Sohail Ali, Mohd Younus, Mohd Bilal. A Review on MowatWilson Disorder, *International Journal of Pharmaceutical Research Scholars*, 2015; V-4, I-3: 176-181.
  23. Humeera Rafeeq\*, Osman Ahmed, Fayeza Ameen, Amreen Sultana, Maryam Fatima. A Review on Harlequin Ichthyosis. *International Journal of Pharmaceutical Research Scholars*, 2015; 4(3): 189-193.
  24. Anees Begum\*, Osman Ahmed. An Assay Method for the Simultaneous Estimation of Albuterol and Ipratropium Bromide using RP- HPLC Technology. *International Journal of Pharmaceutical Research Scholars*, 2016; 5(4): 33-37.
  25. Anas Rasheed\*, Osman Ahmed. UPLC Method Optimisation and Validation for the Estimation of Sodium Cromoglycate in Pressurized Metered Dosage Form, *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(2): 18-24, <http://dx.doi.org/10.21477/ijapsr.v2i2.7774>
  26. Anas Rasheed\*, Osman Ahmed. UPLC Method Development and Validation for the Determination of Chlophedianol Hydrochloride in Syrup Dosage Form. *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(2): 25-31, <http://dx.doi.org/10.21477/ijapsr.v2i2.7775>
  27. Anas Rasheed\*, Osman Ahmed. Validation of a Forced Degradation UPLC Method for Estimation of Beclomethasone Dipropionate in Respules Dosage Form. *Indo American Journal of Pharmaceutical Research*, 2017; 7(05).
  28. Anas Rasheed\*, Osman Ahmed. Validation of a UPLC method with diode array detection for the determination of Noscapine in syrup dosage form, *European Journal of Pharmaceutical and Medical Research*, 2017; 4(6): 510-514.
  29. Anas Rasheed\*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Triamcinolone in syrup dosage form. *World Journal of Pharmaceutical and Life Sciences*, 2017; 3(4): 200-205.
  30. Anas Rasheed\*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Pholcodine in bulk dosage form. *European Journal of Biomedical and Pharmaceutical Sciences*, 2017; 4(6): 572-579.
  31. Anas Rasheed\*, Osman Ahmed. Analytical method development and validation for the determination of Codeine in syrup dosage form using UPLC technology. *World Journal of Pharmaceutical and Life Sciences*, 2017; 3(5): 141-145.
  32. Anas Rasheed\*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Fluticasone propionate in nasal spray inhaler dosage form. *World Journal of Pharmaceutical and Life Sciences*, 2017; 3(5): 168-172.
  33. Anas Rasheed\*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Acetylcysteine in syrup dosage form. *European Journal of Pharmaceutical and Medical Research*, 2017; 4(7): 485-491.
  34. Anas Rasheed\*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Ciclesonide in dry powder inhaler dosage form. *European Journal of Pharmaceutical and Medical Research*, 2017; 4(7): 523-529.
  35. Anas Rasheed\*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Dextromethorphan in syrup dosage form. *European Journal of Pharmaceutical and Medical Research*, 2017; 4(7): 548-554.
  36. Anas Rasheed\*, Osman Ahmed. Analytical Development and Validation of a Stability Indicating Method for the Estimation of Impurities in Budesonide Respules Formulation, *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(3): 46-54. <http://dx.doi.org/10.21477/ijapsr.v2i3.8100>.
  37. Anas Rasheed\*, Osman Ahmed, Analytical Separation and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in Ipratropium Bromide Respules Formulation, *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(3): 55-63. <http://dx.doi.org/10.21477/ijapsr.v2i3.8101>.
  38. Neha Naaz\*, Khaja Uzair ul Hasan, Aaminah Najmus Sahar, Prof. Dr. Osman Ahmed. Plights and

- Predicaments in the Pharmacy Industry. *Indo American Journal of Pharmaceutical Research*, 2017; 7(11).
39. Syed Vakeeluddin\*, Osman Ahmed, Kauser Fathima, Analytical Method Development and Validation for the Simultaneous Estimation of Budesonide and Formoterol in Bulk and Dosage Form Using RP-HPLC Method, *Indo Am. J. P. Sci.*, 2017; 4(07).
  40. Dr. Osman Ahmed\*, Syed Vakeeluddin, Kauser Fathima. A Stability Indicating Method for the Simultaneous Estimation of Budesonide and Formoterol in Bulk and Dosage Form. *Indo American Journal of Pharmaceutical Research*.
  41. Kauser Fathima\*, Dr. Osman Ahmed, Syed Vakeeluddin, Analytical Method Development and Validation for the Simultaneous Estimation of Ofloxacin and Metronidazole in Bulk and Dosage Form Using RP-HPLC, *Indo Am. J. P. Sci.*, 2017; 4(07).
  42. Dr. Osman Ahmed\*, Kauser Fathima, Syed Vakeeluddin. A Stability Indicating Method for the Simultaneous Estimation of Ofloxacin and Metronidazole in Bulk and Dosage Form. *Indo American Journal of Pharmaceutical Research*, 2018; 8(01).
  43. Mohd Shafi, Osman Ahmed, Anas Rasheed, Validation Of A UPLC Method With Diode Array Detection Using C18 Column For The Determination Of Fluorometholone In Parenteral Dosage Form, *Indo Am. J. P. Sci.*, 2018; 05(07).
  44. Validation Of A Forced Degradation Uplc Method For Estimation Of Glibenclamide In Oral Dosage Form, Dr. Osman Ahmed, Mohd Kareem Ahmed and Dr. Anas Rasheed. *World Journal of Pharm. and Life Sci.*, 2019; 5(10): 74-82.
  45. Evaluation and Validation Of A UPLC Method For Simultaneous Estimation Of Glimpiride, Metformin And Voglibose In Oral Dosage Form, Mohd Kareem Ahmed, Dr. Osman Ahmed and Dr. Anas Rasheed. *European Journal Of Biomedical and Pharmaceutical Sciences*, 2019; 6(13): 329-337.
  46. Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Glimpiride, Metformin And Voglibose In Oral Dosage Form Using LCMS, Mohd. Kareem Ahmed, Dr. Osman Ahmed and Dr. Anas Rasheed *European Journal Of Biomedical and Pharmaceutical Sciences*, 2019; 6(13): 338-349.
  47. Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form Dr. Osman Ahmed, Mohd Kareem Ahmed and Dr. Anas Rasheed, *European Journal Of Pharmaceutical And Medical Research*, 2019; 6(12): 494-502.
  48. Evaluation And Validation Of A UPLC Method For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form Dear Dr. Osman Ahmed, Mohd Kareem Ahmed and Dr. Anas Rasheed *European Journal Of Pharmaceutical And Medical Research*, 2019; 6(12): 494-502.
  49. Evaluation And Validation Of A UPLC Method For Estimation Of Amoxycylav In Oral Dosage Form. Dr. Osman Ahmed\*, Sumaiya Fatima and Dr. Anas Rasheed, *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 107-113.
  50. RESPULES \*Sumaiya Fatima, Dr. Osman Ahmed and Dr. Anas Rasheed, *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 68-77.
  51. POLYMORPHISM Sumaiya Fatima\*, Dr. Osman Ahmed and Dr. Anas Rasheed *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 78-93.
  52. Chemical force degradation assay method evaluation for simultaneous estimation of amoxicillin and potassium clavulanate in oral dosage form Sumaiya Fatima\*, Dr. Osman Ahmed and Dr. Anas Rasheed, *European Journal Of Pharmaceutical and Medical Research*, 2020; 7(9): 320-325.
  53. Characterization of force degradation assay method evaluation for simultaneous estimation of amoxicillin and potassium clavulanate in oral dosage form using UPLC-MS/MSN Sumaiya Fatima\*, Dr. Osman Ahmed and Dr. Anas Rasheed *ejbps*, 2020; 7(9): 285-294.
  54. Evaluation and validation of a uplc method for simultaneous estimation of amoxicillin and potassium clavulanate in oral dosage form. Sumaiya Fatima\*, Dr. Osman Ahmed and Dr. Anas Rasheed. *European Journal Of Pharmaceutical And Medical Research*, 2020; 7(9): 326-335.
  55. Spiked force degradation assay method evaluation for estimation of amoxycylav in oral dosage form. Dr. Osman Ahmed\*, Sumaiya Fatima and Dr. Anas Rasheed. *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 185-191.
  56. Anas Rasheed Et.Al; Validation Of A Uplc Method With Diode Array Detection Using C18 Column For The Determination Of Fluorometholone In Parenteral Dosage Form, *Indo American Journal Of Pharmaceutical Sciences*, *Iajps.*, 2016; 5(7): 6209-6215.
  57. Anas Rasheed Et.Al; Analytical Method Development And Validation For The Determination Of Fluorometholone Using C8 Column In Parenteral Dosage Form By Uplc Technology, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2018; 4(8): 106-109.
  58. Anas Rasheed Et.Al; Analytical Stability Indicating Uplc Assay And Validation Using C18 Column For Fluorometholone In Parenteral Dosage Form, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2018; 4(8): 110-114.
  59. Anas Rasheed Et.Al; Validation Of A Forced Degradation Uplc Method Using C8 Column For Fluorometholone In Parenteral Dosage Form, *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2018; 5(8): 311-318.
  60. Anas Rasheed Et.Al; Analytical Separation And Characterisation Of Degradation Products Method

- For The Estimation Of Impurities In Fluorometholone In Parenteral Dosage Form, *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2018; 5(8): 319-324.
61. Anas Rasheed Et.Al; Validation Of A Forced Degradation Uplc Method For Estimation Of Glibenclamide In Oral Dosage Form, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2019; 5(10): 74-82.
  62. Anas Rasheed Et.Al; Evaluation And Validation Of A Uplc Method For Simultaneous Estimation Of Glimepiride, Metformin And Voglibose In Oral Dosage Form, *European Journal Of Biomedical And Pharmaceutical Sciences*, *Ejbps.*, 2019; 13(6): 329-337.
  63. Anas Rasheed Et.Al; Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Glimepiride, Metformin And Voglibose In Oral Dosage Form Using Lcms, *European Journal Of Biomedical And Pharmaceutical Sciences*, *Ejbps.*, 2019; 6(13): 338-349.
  64. Anas Rasheed Et.Al; Evaluation And Validation Of A Uplc Method For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form, *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2019; 6(12): 365-371.
  65. Anas Rasheed Et.Al; Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form, *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2019; 6(12): 494-502.
  66. Anas Rasheed Et.Al; Uplc Method Optimisation And Validation For The Estimation Of Sodium Cromoglycate In Pressurized Metered Dosage Form, *International Journal Of Applied Pharmaceutical Sciences And Research.*, 2017; 2(2): 18-24.
  67. Anas Rasheed Et.Al; Uplc Method Development And Validation For The Determination Of Chlophedianol Hydrochloride In Syrup Dosage Form *International Journal Of Applied Pharmaceutical Sciences And Research*, 2017; 2(2): 25-31.
  68. Anas Rasheed Et.Al; Analytical Method Development And Validation For The Determination Of Codeine In Syrup Dosage Form Using Uplc Technology, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2017; 3(5): 141-145.
  69. Anas Rasheed Et.Al; Validation Of A Uplc Method With Diode Array Detection For The Determination Of Noscapine In Syrup Dosage Form *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2017; 4(6): 510-514.
  70. Anas Rasheed Et.Al; Validation Of A Forced Degradation Uplc Method For Estimation Of Beclomethasone Dipropionate In Respules Dosage Form *Indoamerican Journal Of Pharmaceutical Research*, 2017; 7(05): 8608-8616.